Yardley, PA, United States of America

Jingwu Duan

This inventor holds 52 USPTO granted patents and 1 published patent application and 18 EPO patents, primarily in RORγ Modulators (CPC class C07D). Top assignees: Bristol-Myers Squibb Compnay, Bristol-Myers Squibb Pharma Company, Bristol-Myers Squibb Pharma Corporation. Active years: 2000-2021.

USPTO Granted Patents = 52 

% Patents Active = 98.1

 

Average Co-Inventor Count = 4.0

ph-index = 9

Forward Citations = 298(Granted Patents)

Forward Citations (Not Self Cited) = 291(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Newark, DE (US) (2000 - 2009)
  • Yardley, PA (US) (2005 - 2021)

Company Filing History:


Years Active: 2000-2021

Loading Chart...
Loading Chart...
Areas of Expertise:
RORγ Modulators
TNF Inhibitors
Glucocorticoid Receptor
Heterocyclic Compounds
Tricyclic Sulfones
Matrix Metalloproteinases
Kinase Inhibitors
Pyrrolopyridazine
Azaindazoles
Barbituric Acid Derivatives
Cyclic Compounds
Hydantoins
52 patents (USPTO):Explore Patents

Title: Jingwu Duan - Innovative Inventor from Yardley, PA

Introduction: Jingwu Duan is a talented inventor based in Yardley, PA, known for his groundbreaking contributions to various fields.

Latest Patents: Jingwu Duan holds several patents in the areas of technology and engineering, showcasing his continuous innovation and creativity.

Career Highlights: With a successful career spanning over two decades, Jingwu Duan has worked on numerous projects that have revolutionized industries and improved people's lives.

Collaborations: Throughout his career, Jingwu Duan has collaborated with leading researchers, engineers, and companies to bring his inventions to life and make a significant impact on society.

Conclusion: Jingwu Duan's passion for innovation and his dedication to pushing the boundaries of technology make him a respected figure in the world of inventors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…